Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 5Terminated 4Recruiting 4Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Plasma cell 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 139Rituximab 115Etoposide 77Vincristine 75Doxorubicin 62Cytarabine 61Dexamethasone 58Prednisone 55fludarabine 52Methotrexate 46N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 42Lenalidomide 37Gemcitabine 35Radiotherapy 29Melphalan 27pegaspargase 22Prednisolone 22Ifosfamide 22fludarabine phosphate 20Busulfan 20Cisplatin 19Bendamustine Hydrochloride 19Asparaginase 18Peripheral Blood Stem Cell Transplantation 17ibrutinib 16Decitabine 16Carmustine 16Mercaptopurine 15Filgrastim 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Influenza Vaccines × Lymphoid × Clear all
NCT04626765 2020-11-13

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡